These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18238944)

  • 1. Fenfluramine: riddle or Rosetta stone?
    Weir EK; Obreztchikova M; Hong Z
    Eur Respir J; 2008 Feb; 31(2):232-5. PubMed ID: 18238944
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity.
    Anchors M
    Arch Intern Med; 1997 Jun; 157(11):1270. PubMed ID: 9183245
    [No Abstract]   [Full Text] [Related]  

  • 3. [Valvular heart disease and primary pulmonary hypertension associated with fenfluramine-phentermine].
    Wolf I; Mouallem M; Farfel Z
    Harefuah; 1998 Dec; 135(11):515-7. PubMed ID: 10911468
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug-induced pulmonary hypertension: must history repeat itself?
    Voelkel NF
    Pulm Pharmacol; 1996 Apr; 9(2):67-8. PubMed ID: 8880947
    [No Abstract]   [Full Text] [Related]  

  • 5. Selections from current literature: pharmacological treatment of obesity.
    Connolly J; Verni C; Trilling J; Kelso E; Shiesha S
    Fam Pract; 1998 Feb; 15(1):88-93. PubMed ID: 9527304
    [No Abstract]   [Full Text] [Related]  

  • 6. Fen-phen manufacturers, not physicians, are liable.
    Allen S; Henderson J
    Tex Med; 2000 May; 96(5):62-4. PubMed ID: 10843016
    [No Abstract]   [Full Text] [Related]  

  • 7. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence.
    McCann UD; Seiden LS; Rubin LJ; Ricaurte GA
    JAMA; 1997 Aug; 278(8):666-72. PubMed ID: 9272900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants].
    Goldstein SE; Levy Y; Shoenfeld Y
    Harefuah; 1998 Dec; 135(11):489-92, 568. PubMed ID: 10911459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity, dexfenfluramine, and pulmonary hypertension. A lesson not learned?
    Voelkel NF; Clarke WR; Higenbottam T
    Am J Respir Crit Care Med; 1997 Mar; 155(3):786-8. PubMed ID: 9117009
    [No Abstract]   [Full Text] [Related]  

  • 10. Iowa patients want new anti-obesity drug.
    Belling W
    Iowa Med; 1996 Sep; 86(7):278-9. PubMed ID: 8854575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug-clinics. The hue and cry over central appetite suppressants!].
    Scheen AJ
    Rev Med Liege; 1997 Sep; 52(9):613-5. PubMed ID: 9441348
    [No Abstract]   [Full Text] [Related]  

  • 12. Pulmonary hypertension as a result of drug therapy.
    Higenbottam T; Laude L; Emery C; Essener M
    Clin Chest Med; 2004 Mar; 25(1):123-31. PubMed ID: 15062604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy for obesity -- do the benefits outweigh the risks?
    Manson JE; Faich GA
    N Engl J Med; 1996 Aug; 335(9):659-60. PubMed ID: 8687523
    [No Abstract]   [Full Text] [Related]  

  • 14. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
    Davis R; Faulds D
    Drugs; 1996 Nov; 52(5):696-724. PubMed ID: 9118819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment of obesity with drugs.
    Hirsch J
    Am J Clin Nutr; 1998 Jan; 67(1):2-4. PubMed ID: 9440366
    [No Abstract]   [Full Text] [Related]  

  • 16. Benfluorex: increasing reports of valve disorders.
    Prescrire Int; 2010 Feb; 19(105):17. PubMed ID: 20455335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal effects of fenfluramine-phentermine use.
    Bhattacharyya S; Constantin C; Davar J; Mikhailidis D
    Angiology; 2007 Dec-2008 Jan; 58(6):772-3; author reply 774. PubMed ID: 18216387
    [No Abstract]   [Full Text] [Related]  

  • 18. Appetite-suppressant drugs and the risk of primary pulmonary hypertension?
    Deitel M
    Obes Surg; 1997 Feb; 7(1):3-4. PubMed ID: 9730529
    [No Abstract]   [Full Text] [Related]  

  • 19. Fenfluramine potentiates canine pulmonary vasoreactivity to endothelin-1.
    Barman SA; Isales CM
    Pulm Pharmacol Ther; 1998; 11(2-3):183-7. PubMed ID: 9918753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appetite suppressants and cardiac valvulopathy. Current clinical perspectives.
    Gross SB
    Adv Nurse Pract; 1999 Oct; 7(10):36-40. PubMed ID: 10808770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.